Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: ARRY 614; Pexmetinib hydrochloride

Latest Information Update: 30 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Array BioPharma
  • Class Anti-inflammatories; Antineoplastics; Indazoles; Pyrazoles; Small molecules; Urea compounds
  • Mechanism of Action P38 mitogen-activated protein kinase inhibitors; TIE 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Suspended Myelodysplastic syndromes
  • Discontinued Inflammation

Most Recent Events

  • 17 Oct 2014 Suspended - Phase-I for Myelodysplastic syndromes in USA (PO)
  • 09 Dec 2013 Interim efficacy and adverse events data from a phase I trial in Myelodysplastic syndromes presented at the 55th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2013)
  • 30 Sep 2013 Array BioPharma completes enrolment in a phase I trial for Myelodysplastic syndromes in USA (NCT01496495)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top